8-K: Moleculin Doses First EU Patient in Pivotal AML Trial

Moleculin Biotech announced the enrollment of the first two subjects and treatment of one in the EU for its pivotal Phase 2B/3 MIRACLE trial for relapsed or refractory Acute Myeloid Leukemia (R/R AML).

Summary

• Moleculin Biotech, Inc. (MBRX) has enrolled the first two subjects and treated one in the European Union (EU) for its pivotal Phase 2B/3 MIRACLE trial.
• The trial evaluates Annamycin in combination with cytarabine (AnnAraC) for adult patients with relapsed or refractory acute myeloid leukemia (R/R AML).
• Active recruiting sites are now in the US, Spain, Ukraine, Georgia, and Romania, with more expected to come online by the end of September.
• The company aims to recruit the first 45 subjects for Part A before the end of 2025 for initial efficacy and safety unblinding.
• The MIRACLE study is an adaptive design Phase 2B/3 trial, with data from both portions combined for the primary efficacy endpoint.
• Part A will randomize 75 to 90 subjects (1:1:1) to receive high dose cytarabine (HiDAC) combined with either placebo, 190 mg/m2 of Annamycin, or 230 mg/m2 of Annamycin.
• Preliminary primary efficacy data (Complete Remission or CR) and safety/tolerability for the three arms will be unblinded at 45 subjects.
• The first early unblinding (45 subjects) is expected in the second half of 2025, comprising 30 subjects on Annamycin (190mg/m2 and 230 mg/m2) plus HiDAC and 15 subjects on HiDAC plus placebo.
• The second unblinding (conclusion of Part A at 75-90 subjects) is expected in the first half of 2026.
• This accelerated estimated timeline is partly due to positive investigator response regarding recruitment.
• EU clinical trial approval from EMA requires submission of nonclinical GLP study results before initiating Phase 3 (Part B).
• Part B will randomize approximately 220 additional subjects (1:1) to receive HiDAC plus placebo or HiDAC plus the optimum Annamycin dose, based on safety, pharmacokinetics, and efficacy, consistent with FDA's Project Optimus.
• Annamycin has Fast Track Status and Orphan Drug Designation from the FDA for R/R AML and Orphan Drug Designation for soft tissue sarcoma.
• Annamycin also has Orphan Drug Designation from the EMA for R/R AML.

Sentiment

Score: 7

Explanation: The announcement of first EU patient dosing and being on track for key milestones is positive for clinical progress. However, the explicit mention of needing significant additional financing with no commitments introduces a notable financial risk.

Positives

• First two subjects enrolled and one treated in the EU for the pivotal Phase 2B/3 MIRACLE trial, indicating progress in global expansion.
• Active recruiting sites now include the US, Spain, Ukraine, Georgia, and Romania, with more expected by end of September, demonstrating broad geographical reach.
• The company is on track to recruit the first 45 subjects for Part A before the end of 2025, allowing for early efficacy and safety unblinding.
• An accelerated estimated timeline for unblinding (first half of 2026 for Part A conclusion) is attributed to positive investigator response regarding recruitment.
• Annamycin holds Fast Track Status and Orphan Drug Designation from the FDA for R/R AML, and Orphan Drug Designation for soft tissue sarcoma, potentially expediting development and market access.
• Annamycin also has Orphan Drug Designation from the EMA for R/R AML, supporting its development in Europe.
• The company believes it has substantially de-risked the development pathway for Annamycin for AML following a successful Phase 1B/2 study and FDA input.

Negatives

• EU clinical trial approval was granted under the condition that the company present results of appropriate nonclinical GLP studies before initiating the Phase 3 portion (Part B) of the study, which could introduce a potential hurdle or delay if not met.

Risks

• The ability to recruit the first 45 subjects from Part A before the end of 2025.
• The timing of the release of initial data on the first 45 subjects in the trial.
• The company's ability to reconcile the US and EU protocols with the FDA and EMA, respectively.
• Moleculin will require significant additional financing to conduct its clinical trials as described, for which the company has no commitments.
• Expectations reflected in forward-looking statements may prove to be materially different from actual results.
• Known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. Risk Factors in the most recently filed Form 10-K and updated in Form 10-Q filings and other public SEC filings.

Future Outlook

The company aims to recruit the first 45 subjects for Part A of the MIRACLE trial before the end of 2025, with initial data unblinding expected in the second half of 2025. The conclusion of Part A (75-90 subjects) and second unblinding is anticipated in the first half of 2026. More clinical sites are expected to come online by the end of September. The company also needs to submit nonclinical GLP study results to the EMA before initiating Part B (Phase 3) of the study.

Management Comments

• "For our first site in Spain to have opened up with two subjects enrolled, we believe, indicates the unmet need in treating second line R/R AML." Walter Klemp, Chairman and CEO of Moleculin.
• "All of this, importantly, supports our goal to recruit the first 45 subjects for Part A before the end of 2025 for which efficacy and safety will be unblinded." Walter Klemp, Chairman and CEO of Moleculin.

Industry Context

The development of Annamycin for R/R AML addresses a significant unmet medical need in oncology, as R/R AML patients have limited treatment options and poor prognoses. The adaptive design of the MIRACLE trial, along with Fast Track and Orphan Drug designations, reflects a common strategy in oncology drug development to accelerate promising therapies for severe conditions. The focus on avoiding multidrug resistance and cardiotoxicity positions Annamycin as a potentially differentiated anthracycline in a class of drugs often associated with significant side effects.

Comparison to Industry Standards

• The adaptive design of the Phase 2B/3 MIRACLE trial is consistent with modern clinical trial methodologies, allowing for flexibility and efficiency in drug development, particularly in oncology where patient populations can be challenging to recruit.
• The FDA's Project Optimus initiative, referenced in the trial design for optimal dose selection, is a recent regulatory push to improve dose optimization for oncology drugs, aiming for better efficacy-to-toxicity profiles, aligning Moleculin's approach with current regulatory best practices.
• Annamycin's design to avoid multidrug resistance mechanisms and cardiotoxicity directly addresses key limitations of existing anthracyclines like doxorubicin or daunorubicin, which are foundational in AML treatment but often limited by these issues. This positions Annamycin as a potential improvement over standard-of-care anthracyclines.
• The Fast Track and Orphan Drug Designations from both FDA and EMA for R/R AML are standard incentives provided by regulatory bodies to encourage the development of drugs for serious conditions with unmet needs, indicating the recognized importance of this therapeutic area.

Stakeholder Impact

• Shareholders: Potential for increased value if the clinical trial progresses successfully and Annamycin demonstrates efficacy. However, the need for significant additional financing without commitments poses a dilution risk.
• Patients (R/R AML): The trial offers a potential new treatment option for a severe condition with high unmet need, potentially improving outcomes.
• Medical Community: Successful trial results could lead to a new therapeutic standard for R/R AML.
• Employees: Continued progress in clinical development supports the company's long-term viability and employment.

Next Steps

• Recruit the first 45 subjects for Part A of the MIRACLE trial before the end of 2025.
• Unblind preliminary primary efficacy and safety data for the first 45 subjects in the second half of 2025.
• Bring more clinical sites online by the end of September.
• Submit results of appropriate nonclinical GLP studies to the EMA as a substantial modification to the existing approved CTA before initiating Part B (Phase 3) of the study.
• Conclude Part A (75 to 90 subjects) and perform the second unblinding in the first half of 2026.
• Randomize approximately 220 additional subjects for Part B of the trial.
• Secure significant additional financing to conduct clinical trials.

Key Dates

Recommendation

While the clinical progress with the first EU patient dosing and being on track for initial data unblinding are positive developments for Moleculin Biotech, the explicit disclosure of a need for "significant additional financing" with "no commitments" introduces a substantial financial risk. This potential for future dilution or operational delays due to funding uncertainty warrants a cautious "hold" recommendation, balancing the clinical upside with the financial overhang. Investors should monitor financing developments closely.

Keywords

Moleculin Biotech, MBRX, Annamycin, Acute Myeloid Leukemia, AML, Relapsed Refractory AML, R/R AML, MIRACLE Trial, Phase 3 Clinical Trial, Oncology, Cancer Treatment, Clinical Development, Biotechnology, Pharmaceuticals, Orphan Drug, Fast Track Designation, AnnAraC, Cytarabine, HiDAC